NCT05660135Active, not recruiting
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study
Source: ClinicalTrials.gov · Last updated 24 Aug 2025
Brief summary (registry, in English)
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 13 Dec 2022
- Start date
- 20 Jun 2022
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Diseases
- High blood pressure
- NCT number
- NCT05660135
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 20 Jun 2022 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A person who has a history of administering olomax tablets before participating in this study
Other
- A person who falls under the prohibition of administration according to the permission for olomax tablet
- In addition to the above, a person that the investigator thinks he/she is not suitable for participating in this observation study;
Who the study is looking for
- Adult aged 19 or older at the time of the baseline visit.
- A patient with hypertension and dyslipidemia who is scheduled to administer olomax tablet according to investigator's medical judgement.
- Patients who were previously taking more than two tablets of a single drug, low-density lipoprotein-cholesterol (LDL-C)
- Patients who were previously only taking blood pressure-lowering drugs and did not take LDL-C-lowering drugs, but who need to take additional LDL-C-lowering drugs at the discretion of the researcher
- Patients who were previously taking LDL-C lowering agents and did not take blood pressure lowering agents, but who need to take additional blood pressure lowering agents according to the researcher's judgment
- Patients who have not previously taken both a blood pressure drop and an LDL-C drop but need additional simultaneous use at the discretion of the researcher
- A person who can understand the information provided to him/her and may voluntarily sign a written consent form
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Catholic University of Korea, Seoul ST. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.